- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01692431
The Impact of Fish-oil Fatty Acids on Postprandial Vascular Reactivity (FOFA)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A loss of vascular reactivity and increased vascular tone is being increasingly recognised as a significant cardiovascular disease (CVD) risk factor and highly predictive of future CVD events. A previous study by our group has shown the inclusion of a fish oil mixture administered alongside a high fat meal preserves postprandial vascular function in healthy men [1]. In this three arm, placebo controlled cross over study, the impact of individual fatty acids contained within fish-oil on postprandial vascular reactivity (measured at 4 hour post test meal) will be assessed for the first time. Clinical measurements of vascular function which correlate with CVD risk factors and are predictive of future CVD events will be undertaken in order to assess any potentially beneficial effects. In addition plasma samples will be taken at 0 and 4 hours to determine the change in concentration of modulators of vascular tone. Accordingly, our nutrients of interest which will be administered in the intervention arms of the study, will be present in this lipoprotein rich fraction. By exposing cells in culture to these EPA- and DHA-enriched lipoproteins, mechanisms underlying the vascular response in our human volunteers will be investigated. Finally we will measure the plasma fatty acid profile to confirm that circulating concentrations of EPA and DHA are increasing postprandially according to intake.
As it is now recognised that genetic variation, in addition to being an important determinant of the risk of all known chronic diseases, plays a large part in determining an individual's response to dietary change, DNA will be extracted from whole blood taken at the clinical screening and stored for subsequent genotyping for variants likely to be important in the regulation of EPA and DHA metabolism and vascular tone. Although the current study will not be fully powered to generate definite conclusion regarding genotype*diet interactions, it will serve to generate pilot data for future studies.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Norwich, United Kingdom, NR47TJ
- Norwich Medical School
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
In order to recruit a population at a relative risk of developing CVD of >1.5 males aged 35-55 years, who possess one of the following risk factors for CVD will be recruited through local advertisement:
- Total cholesterol > 6mmol/L
- High density lipoprotein cholesterol (HDLC) < 1.0mmol/L
- Systolic blood pressure > 140 mmHg
- Diastolic blood pressure > 90 mmHg
- Waist circumference > 102cm
Exclusion Criteria:
Current smokers, or ex-smokers ceasing < 3 months ago
Subjects with existing or significant past medical history of vascular disease or any medical condition likely to affect the study measures e.g. vascular disease, circulatory (i.e. Reynaud's), diabetes, systemic lupus erythematosus, hepatic, renal, digestive, haematological, neurological, cancer or thyroidal disease.
Those with known allergies to the intervention foods / commercially available supplements.
Those unprepared to adhere to dietary restrictions during the trial i.e. for 3 days preceding each assessment visit (and for a 3 day run-in period) or unwilling to comply with the assessments per protocol.
Parallel participation in another research project which involves concurrent dietary intervention and/or sampling of biological fluids/material.
Having vaccinations (excluding the flu vaccination) or antibiotics within 3 months of start of trial, and those with vaccinations scheduled for during the trial.
Taking EPA or DHA containing food / dietary supplements likely to affect the study results e.g. supplements derived from marine organisms which equate to a greater than 1 gram of EPA and DHA per daily serving. Prospective participants who are willing to cease supplementation 2 month preceding, and during, the trial will be considered on a case by case basis.
Habitual consumption of more than one portion of oily fish per week (as defined as 140g of any oil fish, including salmon, trout, mackerel, sardines, pilchards, herring, kipper, eel, whitebait, etc).
Prescribed lipid lowering, medicine affecting lipoprotein metabolism or blood blotting, hypertension, vasodilators (e.g. Viagra) or antibiotic medication.
Assessed from the clinical screening.
Unsatisfactory biochemical or haematological assessment assessed by the studies clinical advisor
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DHA
High fat meal containing DHA rich oil.
|
High fat meal containing DHA
|
Experimental: EPA
High fat meal containing EPA.
|
High fat meal containing EPA
|
Placebo Comparator: Control
High fat meal with no/negligable omega-3 fatty acid content.
|
High fat meal containing negligible EPA/DHA content
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Endopat
Time Frame: Change from baseline at 4 hours postprandially
|
EndoPat is an easy to use and rapid technique which has been validated against other clinically accepted measures of endothelial function such as Flow Mediated Dilation and Coronary Blood Flow measured by angiography alongside acetylcholine infusion.
EndoPat has also been shown to correlate with multiple known CVD risk factors and to be predictive of future cardiovascular events.
In addition, EndoPat will be utilised alongside oral administration of nitroglycerin in order to establish if peripheral arterial tone is altered in response to EPA or DHA in a non-Nitric Oxide dependent manner.
EndoPAT produces a reactive hyperaemic index score which is indicative of the endothelial's capacity to produce NO, which itself is indicative of general endothelial function.
EndoPAT will be assessed using a standardised methodology developed by Itamar Medical, which involves measuring changes in dilation in response to induced hyperaemia.
|
Change from baseline at 4 hours postprandially
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pulse Wave Velocity
Time Frame: Change from baseline at 4 hours postprandially
|
Pulse Wave Velocity (PWV) analysis will also be utilised in order to measure arterial stiffness.
PWV analysis will allow several non-invasive measurements to be taken simultaneously including PWV, which is an established index of arterial stiffness, and augmentation index, an indirect measure of arterial stiffness which is dependent on wave-reflections and independent of pulse pressure.
PWV and associated measures will be measured using methodology developed by Skidmore medical.
PWV is measured in m/sec while augmentation index is measured as a % of augmentation (of central aortic pressure by a reflected pulse wave).
|
Change from baseline at 4 hours postprandially
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anne Marie Minihane, PhD, University of East Anglia
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 12/EE/011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Eicosapentaenoic Acid
-
Qualitas HealthArizona State UniversityCompletedTriglycerides | Cholesterol | Eicosapentaenoic Acid | Omega-3United States
-
Wroclaw Medical UniversityUnknownCardiovascular Diseases | Preventive Medicine | Fatty Acids | Anti-Inflammatory Agents | Eicosapentaenoic Acid | Preventive Health Services | Alpha-Linolenic Acid | Docosahexaenoic AcidsPoland
-
Massachusetts General HospitalNational Institutes of Health (NIH)CompletedColorectal Cancer | Colorectal Adenoma | Gastrointestinal Microbiome | Endoscopic Surgery | Eicosapentaenoic AcidUnited States
-
Children's Hospital Medical Center, CincinnatiCompletedBile Acid Synthesis Defect | Inborn Error of Bile Acid Metabolism | Inborn Error of Bile Acid ConjugationUnited States
-
University of TorontoCompletedProtein/Amino Acid Metabolism | Indicator Amino Acid Oxidation MethodCanada
-
Sheba Medical CenterUnknownCord Blood Amino Acid Profile | Fetal Amino Acid Profile in Different Gestational Ages | Infant Amino Acid Profile at Day 3 and DischargeIsrael
-
Institut National de la Recherche AgronomiqueCompleted
-
University of Eastern FinlandCompleted
-
Queen's UniversityCanadian Institutes of Health Research (CIHR)Terminated
-
University Hospital OlomoucCompletedAcid Base Imbalance
Clinical Trials on DHA
-
University of New MexicoNational Center for Research Resources (NCRR)TerminatedPregnancy | Randomized Clinical Trial | Docosahexaenoic AcidUnited States
-
University of Alabama at BirminghamMead Johnson NutritionNot yet recruitingPremature | Infant Malnutrition | Nutrition Disorder, Infant | Light-For-Dates With Signs of Fetal MalnutritionUnited States
-
Pontificia Universidad Catolica de ChileCompletedObesity | Body CompositionChile
-
Emory UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
SCF PharmaCompleted
-
National Science Council, TaiwanCompletedMajor Depressive DisorderTaiwan
-
University of OxfordMahidol University; Mahidol Oxford Tropical Medicine Research UnitCompletedHealthy | Pharmacokinetics | Drug CombinationThailand
-
National Institute of Diabetes and Digestive and...Completed
-
Hospices Civils de LyonCompleted
-
DSM Nutritional Products, Inc.SynteractHCRCompleted